ASTRAZENECA PLC
AZNNYSETrading Snapshot
- Day Range
- $167.96 – $171.94
- 52-Week Range
- $153.41 – $212.71
- Volume (shares)
- 1,697,959
- Avg Volume (shares)
- —
- Shares Outstanding
- 1.55B
- Next Earnings
- 2026-10-30
Fundamentals Snapshot
- Annual Revenue
- $58.74B
- Last Q Revenue
- $15.38B
- P/E Ratio
- 25.3
- P/S Ratio
- 4.3x
- EPS (TTM)
- $6.73
- Dividend Yield
- 1.87%
- Dilution (1yr)
- +0.0%
ASTRAZENECA PLC
AZN
StockOtter · stockotter.spaceAbout ASTRAZENECA PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
AstraZeneca and Mark-Paul Gosselaar Launch Meet Your Mark to Raise Awareness of Cancer Biomarker Testing
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the launch of Meet Your Mark, a new public health campaign featuring actor Mark-Paul Gosselaar. The campaign encourages people to ask about biomarker testing
Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors
After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well following a strong earnings b
Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research
TORONTO--(BUSINESS WIRE)--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve care for Canadians living with a
Parnassus Value Equity Fund Q3 2026 Portfolio Review
Parnassus Value Equity Fund (Investor Shares) returned -1.38% (net of fees) for the quarter, underperforming the Russell 1000 Value Index's 2.61%. Top contributors include Thermo Fisher, CME Group, NICE, Willis Towers Wa
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
Astrazeneca NYSE: AZN highlighted new clinical data across bladder, lung and gastric cancers at its ESMO 2026 investor event, including four presidential presentations that executives said support the company's oncology
Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
DENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews. com) - Eli Lilly (NYSE: LLY), Novo Nordisk (NYSE: NVO), AstraZeneca (NYSE: AZN), and Roche (OTCQX: RHHBY) are among the biopharma companies committing billions of